Definitive chemoradiotherapy for squamous head and neck cancer: Cisplatin versus carboplatin? A meta-analysis

Pedro Nazareth Aguiar, Hakaru Tadokoro, Gislaine Fernandes Da Silva, Mayndra Mychelle Landgraf, Carmelia Maria Noia Barreto, Bruno Andraus Filardi, Gilberto De Lima Lopes, Pedro Oliveira, Ramon Andrade De Mello

Research output: Contribution to journalArticle

Abstract

Aim: Concomitant chemoradiotherapy (with cisplatin or carboplatin) is an option of definitive treatment for squamous head and neck cancer. We aimed to perform a meta-analysis comparing those two platinum agents. Materials & methods: We carried out a systematic search on English literature between 1990 and 17 April 2015 according to the Cochrane review guidelines. Results: Five of 60 studies fulfilled inclusion criteria with 491 patients. There was no difference in response rate. Cisplatin tends to be more active systemically than carboplatin, without statistically significance; 5-year survival rate: 30 and 27%, respectively (p = 0.33). Conclusion: Despite the trend to improved outcomes in using cisplatin, carboplatin is also active and can be a reasonable option to treat patients.

Original languageEnglish (US)
Pages (from-to)2755-2764
Number of pages10
JournalFuture Oncology
Volume12
Issue number23
DOIs
StatePublished - Dec 1 2016
Externally publishedYes

Keywords

  • carboplatin
  • chemoradiotherapy
  • chemotherapy
  • cisplatin
  • head and neck

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Definitive chemoradiotherapy for squamous head and neck cancer: Cisplatin versus carboplatin? A meta-analysis'. Together they form a unique fingerprint.

Cite this